These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

686 related articles for article (PubMed ID: 23074134)

  • 41. Generic immunosuppressants in hematopoietic cell transplantation.
    Cutler C; Kesselheim A; Gabardi S; Andersson BS; Carpenter P; Khoury HJ; Litzow M; Rowley SD; Lanum S; Leather H; Tina Shih YC; Gale RP; Wingard JR; Appelbaum FR; Anasetti C;
    Biol Blood Marrow Transplant; 2011 Mar; 17(3):285-90. PubMed ID: 21087678
    [No Abstract]   [Full Text] [Related]  

  • 42. Conversion to sirolimus-based maintenance immunosuppression using daclizumab bridge therapy in renal transplant recipients.
    Sundberg AK; Rohr MS; Hartmann EL; Adams PL; Stratta RJ
    Clin Transplant; 2004; 18 Suppl 12():61-6. PubMed ID: 15217410
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Reduced C0 concentrations and increased dose requirements in renal allograft recipients converted to the novel once-daily tacrolimus formulation.
    de Jonge H; Kuypers DR; Verbeke K; Vanrenterghem Y
    Transplantation; 2010 Sep; 90(5):523-9. PubMed ID: 20592652
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Conversion to tacrolimus and atorvastatin in cyclosporine-treated heart transplant recipients with dyslipidemia refractory to fluvastatin.
    Skalicka B; Kubanek M; Malek I; Vymetalova Y; Hoskova L; Podzimkova M; Kautzner J
    J Heart Lung Transplant; 2009 Jun; 28(6):598-604. PubMed ID: 19481021
    [TBL] [Abstract][Full Text] [Related]  

  • 45. A UK analysis of the cost of switching renal transplant patients from an immediate-release to a prolonged-release formulation of tacrolimus based on differences in trough concentration variability.
    Muduma G; Odeyemi I; Pollock RF
    J Med Econ; 2014 Jul; 17(7):520-6. PubMed ID: 24754700
    [TBL] [Abstract][Full Text] [Related]  

  • 46. 12-month follow-up analysis of a multicenter, randomized, prospective trial in de novo liver transplant recipients (LIS2T) comparing cyclosporine microemulsion (C2 monitoring) and tacrolimus.
    Levy G; Grazi GL; Sanjuan F; Wu Y; Mühlbacher F; Samuel D; Friman S; Jones R; Cantisani G; Villamil F; Cillo U; Clavien PA; Klintmalm G; Otto G; Pollard S; McCormick PA
    Liver Transpl; 2006 Oct; 12(10):1464-72. PubMed ID: 17004259
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Optimal everolimus concentration is associated with risk reduction for acute rejection in de novo renal transplant recipients.
    Chan L; Hartmann E; Cibrik D; Cooper M; Shaw LM
    Transplantation; 2010 Jul; 90(1):31-7. PubMed ID: 20517177
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Two-year experience with tacrolimus in renal transplantation after late conversion from cyclosporine therapy.
    Videla CO
    Transplant Proc; 2009; 41(6):2659-63. PubMed ID: 19715995
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Pharmacokinetics in stable heart transplant recipients after conversion from twice-daily to once-daily tacrolimus formulations.
    Alloway R; Vanhaecke J; Yonan N; White M; Haddad H; Rábago G; Tymchak W; Diaz Molina B; Grimm M; Eiskjaer H; Karpf C; Undre N
    J Heart Lung Transplant; 2011 Sep; 30(9):1003-10. PubMed ID: 21493098
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Bioavailability, Efficacy and Safety of Generic Immunosuppressive Drugs for Kidney Transplantation: A Systematic Review and Meta-Analysis.
    Tsipotis E; Gupta NR; Raman G; Zintzaras E; Jaber BL
    Am J Nephrol; 2016; 44(3):206-18. PubMed ID: 27576318
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Two years postconversion from a prograf-based regimen to a once-daily tacrolimus extended-release formulation in stable kidney transplant recipients.
    Alloway R; Steinberg S; Khalil K; Gourishankar S; Miller J; Norman D; Hariharan S; Pirsch J; Matas A; Zaltzman J; Wisemandle K; Fitzsimmons W; First MR
    Transplantation; 2007 Jun; 83(12):1648-51. PubMed ID: 17589351
    [TBL] [Abstract][Full Text] [Related]  

  • 52. A 39-month follow-up study to evaluate the safety and efficacy in kidney transplant recipients treated with modified-release tacrolimus (FK506E)-based immunosuppression regimen.
    Han DJ; Park JB; Kim YS; Kim SJ; Ha J; Kim HC; Kim SJ; Moon IS; Yang CW
    Transplant Proc; 2012 Jan; 44(1):115-7. PubMed ID: 22310592
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Therapeutic monitoring of pediatric renal transplant patients with conversion to generic cyclosporin.
    Riva N; Guido PC; Ibañez J; Licciardone N; Rousseau M; Mato G; Monteverde M; Schaiquevich P
    Int J Clin Pharm; 2014 Aug; 36(4):779-86. PubMed ID: 24861769
    [TBL] [Abstract][Full Text] [Related]  

  • 54. A pharmacodynamic investigation of tacrolimus in pediatric liver transplantation.
    Staatz CE; Taylor PJ; Lynch SV; Tett SE
    Liver Transpl; 2004 Apr; 10(4):506-12. PubMed ID: 15048793
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Effect of long-term tacrolimus immunosuppression on renal function in liver transplant recipients.
    Corman SL; Coley KC; Schonder KS
    Pharmacotherapy; 2006 Oct; 26(10):1433-7. PubMed ID: 16999653
    [TBL] [Abstract][Full Text] [Related]  

  • 56. [Special considerations in generic substitution of immunosuppressive drugs in transplantation].
    Remport A; Dankó D; Gerlei Z; Czebe K; Kiss I
    Orv Hetil; 2012 Aug; 153(34):1341-9. PubMed ID: 22913916
    [TBL] [Abstract][Full Text] [Related]  

  • 57. A switch from conventional twice-daily tacrolimus to once-daily extended-release tacrolimus in stable kidney transplant recipients.
    Hatakeyama S; Fujita T; Yoneyama T; Yoneyama T; Koie T; Hashimoto Y; Saitoh H; Funyu T; Narumi S; Ohyama C
    Transplant Proc; 2012 Jan; 44(1):121-3. PubMed ID: 22310594
    [TBL] [Abstract][Full Text] [Related]  

  • 58. The impact of conversion from prograf to generic tacrolimus in liver and kidney transplant recipients with stable graft function.
    Momper JD; Ridenour TA; Schonder KS; Shapiro R; Humar A; Venkataramanan R
    Am J Transplant; 2011 Sep; 11(9):1861-7. PubMed ID: 21714845
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Clinical outcomes of renal transplantation using liquid chromatographic monitoring of tacrolimus.
    Borrows R; Chusney G; Loucaidou M; James A; Stichbury J; Van Tromp J; Cairns T; Griffith M; Hakim N; McLean A; Palmer A; Papalois V; Taube D
    Ther Drug Monit; 2006 Apr; 28(2):269-73. PubMed ID: 16628143
    [TBL] [Abstract][Full Text] [Related]  

  • 60. De novo kidney transplant recipients need higher doses of Advagraf compared with Prograf to get therapeutic levels.
    Crespo M; Mir M; Marin M; Hurtado S; Estadella C; Gurí X; Rap O; Moral R; Puig JM; Lloveras J
    Transplant Proc; 2009; 41(6):2115-7. PubMed ID: 19715848
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 35.